The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.

PubWeight™: 3.22^‹?› | Rank: Top 1%

🔗 View Article (PMID 32283152)

Published in J Infect on April 10, 2020

Authors

Author Affiliations

1: National Clinical Research Center for Child Health, National Children's Regional Medical Center, the Children's Hospital, Zhejiang University School of Medicine, No 3333, Binsheng Road, Hangzhou 310052, China.
2: National Clinical Research Center for Child Health, National Children's Regional Medical Center, the Children's Hospital, Zhejiang University School of Medicine, No 3333, Binsheng Road, Hangzhou 310052, China. Electronic address: maojh88@zju.edu.cn.

Associated clinical trials:

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 | NCT04377503

COVID-19 Convalescent Plasma (CCP) Transfusion | NCT04412486

Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19 | NCT04457349

Estradiol and Progesterone in Hospitalized COVID-19 Patients | NCT04865029

RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow | NCT05062681

Articles citing this ↘

Interleukin-17: A potential therapeutic target in COVID-19. J Infect (2020) 1.40

Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect (2020) 0.75

Interleukin-6 as prognosticator in patients with COVID-19. J Infect (2020) 0.75